Ofatumumab is a humanised anti-CD20 monoclonal antibody whose epitope is distinct from that of rituximab. The CD20 antigen is expressed on solely B cell lymphocytes. Compared with rituximab, ofatumumab binds more tightly to CD20 with a slower off-rate. Ofatumumab causes cytotoxicity in the cells that express CD20 by means of complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC).
| Molecular Weight | 146059.83 |
| Formula | C6480H10022N1742O2020S44 |
| CAS Number | 679818-59-8 |
| Form | Liquid |
| Storage | -80°C for long term |
| Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
| Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
| Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
| Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
[1] Lin TS, et al. Pharmgenomics Pers Med. Ofatumumab: a novel monoclonal anti-CD20 antibody.
| Related CD20 Products |
|---|
| Epcoritamab
Epcoritamab is a novel bispecific IgG1k/λ antibody targeting CD3 and CD20 that activates T cells and directs them to kill malignant CD20+ B cells.Epcoritamab has antitumor activity and may be used in studies related to RR diffuse large B-cell lymphoma (DLBCL). |
| Zebituzumab
Zebituzumab (zebituzumab) is a recombinant human-mouse chimeric anti-CD20 monoclonal antibody that can be used in studies related to CD20-positive diffuse large B-cell lymphoma. |
| Veltuzumab
Veltuzumab (IMMU-106) is a humanized anti-CD20 monoclonal antibody. Veltuzumab has low EC50 value of 0.08-0.09 μg/mL in the Daudi cell line. Veltuzumab can be used for the research of cancer including non-Hodgkin lymphoma (NHL). |
| Divozilimab
Divozilimab (BCD-132) is a humanized anti-CD20 IgG1ҡ monoclonal antibody for use in studies related to multiple sclerosis. |
| Zuberitamab
Zuberitamab (HS006) is a monoclonal antibody that targets CD20 and can be used in cancer research, including diffuse large B-cell lymphoma. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
